SCHEMBL4181048

SCHEMBL4181048

COc1cccc2cc(CO)c(-c3cccc(F)c3)nc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 4/20 0.43
PDGFRB P09619 1/20 0.42
PDGFRA P16234 1/20 0.42
DHPS P49366 1/20 0.42
NTRK1 P04629 1/20 0.42
PTGDR2 Q9Y5Y4 2/20 0.40
CTSA P10619 3/20 0.40
PDE3B Q13370 1/20 0.40
PDE3A Q14432 1/20 0.40
USP2 O75604 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
CYP2C19 P33261 1/20 0.39
PDE4A P27815 1/20 0.39
PDE4C Q08493 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4185069 0.88 PDE4B (0.43) PDE4BPDGFRBPDGFRADHPSNTRK1
SCHEMBL10251531 0.88 PDE4B (0.43) PDE4BPDGFRBPDGFRADHPSNTRK1
SCHEMBL1886897 0.87 PDE10A (0.46) PDE4BPDE3BPDE3AALDH1A1CYP1A2
Hydrochloric Acid SCHEMBL4178752 0.86 PDE4B (0.42) PDE4BPDGFRBPDGFRADHPSNTRK1
SCHEMBL12014806 0.84 PDGFRB (0.51) PDE4BPDGFRBPDGFRADHPSNTRK1
SCHEMBL27781235 0.82 PDE4B (0.39) PDE4BPDGFRBPDGFRADHPSNTRK1
SCHEMBL27781175 0.79 PDE3B (0.46) PDE4BPDGFRBPDGFRANTRK1CTSA
SCHEMBL4167658 0.78 PDE4B (0.43) PDE4BPDGFRBPDGFRANTRK1CTSA
SCHEMBL1886039 0.74 KDM4E (0.51) PDE4BPDE3BPDE3AALDH1A1CYP1A2
SCHEMBL17928653 0.74 NTRK1 (0.43) PDE4BNTRK1USP2ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200048265-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2020-02-13 US disclosed
US-20180105532-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2018-04-19 US disclosed
US-9873701-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2018-01-23 US disclosed
EP-3045458-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES Amgen, Inc (US) 2016-07-20 EP disclosed
EP-2137186-B1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC (US) 2016-01-27 EP disclosed
US-20150045361-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC (US) 2015-02-12 US disclosed
US-8901135-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-12-02 US disclosed
US-8586739-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2013-11-19 US disclosed
US-20120220585-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-08-30 US disclosed
US-20120220586-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-08-30 US disclosed
CN-101715453-B Heterocyclic compounds and their uses AMGEN INC 2012-06-27 CN disclosed
US-8193199-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2012-06-05 US disclosed
CN-101715453-A Heterogeneous ring compound and application thereof AMGEN INC 2010-05-26 CN disclosed
EP-2137186-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES Amgen Inc. (US) 2009-12-30 EP disclosed
US-20090137581-A1 Heterocyclic compounds and their uses AMGEN INC. 2009-05-28 US disclosed
WO-2008118468-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048265-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, BCL9, MALT1 PDE4B 2387/4885PDGFRB 604/4885PDGFRA 745/4885
US-20090137581-A1 Heterocyclic compounds and their uses MCL1, BCL9, MALT1 PDE4B 2387/4885PDGFRB 604/4885PDGFRA 745/4885
US-20120220586-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, BCL9, MALT1 PDE4B 2387/4885PDGFRB 604/4885PDGFRA 745/4885
US-20150045361-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, BCL9, MALT1 PDE4B 2387/4885PDGFRB 604/4885PDGFRA 745/4885
US-20180105532-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, BCL9, MALT1 PDE4B 2387/4885PDGFRB 604/4885PDGFRA 745/4885
US-20120220585-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, BCL9, MALT1 PDE4B 2387/4885PDGFRB 604/4885PDGFRA 745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.